FFR CT Analysis for Coronary Artery Functional Assessment

Request Demo

DEEPVESSEL FFR is FDA Cleared, CE Marked, and NMPA Approved. 

DeepVessel FFR software displayed on desktop

Improving Diagnosis & Treatment of Patients with Coronary Artery Disease with FFR CT

DEEPVESSEL FFR ( DVFFR) is a software medical device that uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using coronary computed tomography angiography. The software processes coronary CTA images semi-automatically, generates a three-dimensional model of the coronary artery tree, and computes non-invasive DVFFR values. A PDF report of the derived information is sent electronically to physicians. DEEPVESSEL FFR is intended to support the functional evaluation of coronary artery disease.

DEEPVESSEL FFR applies DeepVessel and DeepFFR techniques, Keya Medical’s proprietary deep learning technologies built on the latest advances in computer vision and medical image analysis. This new approach gives a strong performance advantage with fast processing speed and accurate non-invasive FFR analysis.

How it Works

Clinician sends coronary CTA DICOM images to Keya Medical


Deep learning algorithms and Keya Medical trained analysts perform the DeepVessel FFR analysis


An interactive report and 3D model of the coronary arteries is sent electronically to the clinician for review

Product Features


Non-invasive functional assessment from CTA scan


Enables accurate and fast FFR analysis


Provides both anatomical and functional information


Novel coronary CT FFR technique driven by AI


Reduces medical cost


FDA cleared
CE marked



Calculates non-invasive DVFFR values from coronary CTA images to reduce unnecessary coronary catheterizations


Achieves 90% diagnostic accuracy using invasive FFR as the ground truth


Provides both anatomical and functional information to improve clinical decision making


Delivers results to clinicians quickly for timely decision making


Results can be viewed on mobile, PC, and tablet devices


Reduces costs from invasive procedures and unnecessary therapies

Clinical Trials Performance Assessment

Keya Medical conducted prospective[1] and retrospective multicenter, self-controlled studies in 2017 and 2019. In these trials, FFR measured invasively using a pressure wire was used as the gold standard to evaluate the sensitivity and specificity of DeepVessel FFR in evaluating functional myocardial ischemia in patients with stable coronary artery disease.

2017 Clinical Trial

In 2017, DeepVessel FFR was tested via a multi-center prospective clinical trial in which patients were recruited from:

  • Beijing Anzhen Hospital affiliated to Capital Medical University
  • Air Force General Hospital PLA
  • Cangzhou Central Hospital
Study results demonstrated:
Accuracy 89.2%
Sensitivity 94.2%
Specificity 84.3%
Positive Predictive Value 86.9%
Negative Predictive Value 92.2%

2019 Clinical Trial

In 2019, DeepVessel FFR was tested via a multi-center retrospective clinical trial in which patients were recruited from:

  • Beijing Anzhen Hospital affiliated with Capital Medical University
  • Fuwai Hospital, Chinese Academy of Medical Sciences
  • Beijing Friendship Hospital
  • The First Affiliated Hospital of Wenzhou Medical University
  • The Second Affiliated Hospital of Zhejiang University Medical College
  • Wuhan Asia Heart Hospital
Study results demonstrated:
Accuracy 90.8%
Sensitivity 94.7%
Specificity 88.6%
Positive Predictive Value 83.0%
Negative Predictive Value 96.7%


[1] Wang ZQ, Zhou YJ, Zhao YX, et al. Diagnostic accuracy of a deep learning approach to calculate FFR from coronary CT angiography. J Geriatr Cardiol 2019;16:42-48.

Learn more about DEEPVESSEL FFR

We are actively looking for clinical partners in the United States and European Union.